Sells an implanted system that monitors brain activity and delivers targeted stimulation to treat adults with drug-resistant focal epilepsy, primarily through hospitals and comprehensive epilepsy centers.
10-K for FY2025, filed Mar 3, 2026We are a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence…View ↗
Epilepsy is further classified into two main categories– focal epilepsy and generalized epilepsy. Approximately 60% of epilepsy patients…View ↗
The Company derives most of its revenue from sales of RNS Systems to hospital facilities (typically comprehensive epilepsy centers, or…View ↗
Hospitals buy RNS systems and related products, with sales occurring when the device is implanted or, for advance orders, delivered; hospitals also pay for clinician access to the data platforms over the access period. Rapport pays for biomarker monitoring over its support period and for data analysis when the work is completed.
10-K for FY2025, filed Mar 3, 2026The Company derives most of its revenue from sales of RNS Systems to hospital facilities (typically comprehensive epilepsy centers, or…View ↗
At contract inception, the Company assesses the products or services promised within each contract and determines those that are…View ↗
The Company typically delivers its RNS System and related products to a hospital on the date of the scheduled procedure. There is no…View ↗
The Company also ships the RNS System and related products to customers who place orders ahead of scheduled procedures. Such orders or…View ↗
The Company recognizes service revenue related to the PDMS and the nSight Platform on a ratable basis over the period in which the Company…View ↗
The Company recognizes revenue under its contract with Rapport to provide biomarker monitoring and data analysis services. Revenue from…View ↗
$100M
10-K for FY2025, filed Mar 3, 2026
$100M ↗
Hospitals, typically comprehensive epilepsy centers, buy RNS systems; the company’s sales team works directly with prescribing epileptologists and implanting neurosurgeons. Rapport Therapeutics also buys biomarker-monitoring and data-analysis services.
10-K for FY2025, filed Mar 3, 2026We received Pre-Market Approval, or PMA, from the FDA for our RNS System in late 2013 and began the commercial rollout of our RNS System in…View ↗
The Company derives most of its revenue from sales of RNS Systems to hospital facilities (typically comprehensive epilepsy centers, or…View ↗
The Company recognizes revenue under its contract with Rapport to provide biomarker monitoring and data analysis services. Revenue from…View ↗
No. It lost $21.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$3.3MView ↗
8-K, filed Nov 12, 2026
Revises full year 2026 revenue guidance to $91 million to $92 million; focused on improving commercial execution and accelerating growthView ↗
Growing. Revenue grew 2.2x in 4 years, from $45.2M in FY2021 to $100M in FY2025, about 22% a year.
Broader clinician reach
The older report describes sales focused on comprehensive epilepsy centers. The latest report adds outreach to epileptologists outside those centers and functional neurosurgeons, widening the clinician base the sales team targets.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 3, 2026
Competes with LivaNova and Medtronic
10-K for FY2025, filed Mar 3, 2026We estimate that approximately 80% of drug-resistant focal epilepsy patients are either not ideal candidates for ablative or resective…View ↗
Loading...